Scientific Advisors

Bluefield benefits from the skilled guidance of established leaders whose diverse expertise in discovery research, clinical science and drug development helps move us toward a cure.

Internal Advisory Board (IAB)

Bob Farese, M.D.
Professor of Genetics and Complex Diseases
Harvard T.H. Chan School of Public Health

Joachim Herz, M.D.
Thomas O. and Cinda Hicks Family Distinguished Chair in Alzheimer’s Disease Research
UT Southwestern Medical Center

Dione Kobayashi, Ph.D.
Executive Scientist
Myonexus Therapeutics, Inc

Ian Massey, Ph.D.
Independent Consultant
Synosia Consulting

Bruce Miller, M.D.
A.W. and Mary Margaret Clausen Distinguished Professor in Neurology &
Director, Memory and Aging Center
University of California, San Francisco

Lennart Mucke, M.D.
Director and Senior Investigator, Gladstone Institute of Neurological Disease
Professor of Neurology and Neuroscience, University of California, San Francisco

Scientific Advisory Board (SAB)

The Bluefield Scientific Advisory Board is composed of world-recognized leaders in clinical and basic research. They evaluate current research, advise on funding decisions and provide strategic advice in support of our mission to find a cure or treatment for frontotemporal dementia.

Steven B. Miller, M.D.*
Senior Vice President and Chief Medical Officer
Express Scripts, Inc.

David Holtzman, M.D.
Andrew B. and Gretchen P. Jones Professor and Chairman of Neurology
Professor of Developmental Biology
Associate Director of the Alzheimer's Disease Research Center
Washington University in St. Louis School of Medicine

David Knopman, M.D.
Professor of Neurology
Mayo Clinic, Minnesota

Kenneth S. Kosik, M.D.
Harriman Professor of Neuroscience
University of California, Santa Barbara

Ian Massey, Ph.D.
Independent Consultant
Synosia Consulting

William C. Mobley, M.D., Ph.D.
Distinguished Professor and Chair, Department of Neurosciences
Executive Director of UCSD's Down Syndrome Center for Research and Treatment
University of California, San Diego